Clinical Trials
38 trialsConsolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial
University of Washington
Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
Case Comprehensive Cancer Center
A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer
Memorial Sloan Kettering Cancer Center
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
University of Washington
TRIFECTA
University of Washington
A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy
Memorial Sloan Kettering Cancer Center
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Mayo Clinic
REDEMPTED
Brazilian Clinical Research Institute
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
Ohio State University Comprehensive Cancer Center
NEOBLAST
RenJi Hospital
FUTURE
IRCCS San Raffaele
RAD-VACCINE
The Methodist Hospital Research Institute
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
UNC Lineberger Comprehensive Cancer Center
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
University of Washington
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
DIVON
Sun Yat-sen University
Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt
Regina Elena Cancer Institute
CIMMIS
Fundacio Puigvert
3 Tesla MRI in Patients With Bladder Cancer
University of Cincinnati
ABATE
Hoosier Cancer Research Network
RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
Zhujiang Hospital
Infectious Complications After Cystectomy: A Prospective Observational Study
Ludwig-Maximilians - University of Munich
Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy
IRCCS San Raffaele
Comparing Operative, Postoperative and Quality of Life of Patients After Salvage and Radical Cystectomy
Assiut University
MOSAIC
Aarhus University Hospital
RACE IT
Technical University of Munich
Efficacy and Safety of Clinical Telesurgery Using Chinese Independently Developed Surgical Robot System
The Affiliated Hospital of Qingdao University
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
University of Southern California
Robotic Radical Cystectomy Outcomes
University of Florence
Study Comparing Open Radical Cystectomy With Robot-assisted Cystectomy in Patients With Bladder Cancer
Rigshospitalet, Denmark
Research on the Combined-Modality Treatment Model of Bladder Preservation in Muscular Invasive Bladder Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Ileal Conduit Versus Cutaneous Ureterostomy After Radical Cystectomy
Assiut University
Multi-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Protocol of the Italian Radical Cystectomy Registry
University of Roma La Sapienza
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
University of Washington
Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer
UNC Lineberger Comprehensive Cancer Center
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer
University of Michigan Rogel Cancer Center